BackgroundCheck.run
Search For

Wen Xie, 54905 Wellesley Ave, Pittsburgh, PA 15206

Wen Xie Phones & Addresses

905 Wellesley Ave, Pittsburgh, PA 15206    412-3620529   

401 Shady Ave, Pittsburgh, PA 15206    412-3620529   

South El Monte, CA   

San Diego, CA   

Birmingham, AL   

Baton Rouge, LA   

Mentions for Wen Xie

Resumes

Resumes

Wen Xie Photo 1

Wen Xie

Location:
United States

Business Records

Name / TitleCompany / ClassificationPhones & Addresses
Wen Xie
Phd
The University of Pittsburgh 3501 Trc St 566, Pittsburgh, PA 15261
412-3839911
Wen Xie Winfund Investment LLC 18340 Colima Rd, Whittier, CA 91748
12732 Foothill Blvd, Rancho Cucamonga, CA 91739
Wen Xie
Owner
Gene's Cleaners & Laundry 3846 Peck Rd, El Monte, CA 91732
626-4443784
Wen Xie Jv Azalea LLC 17588 Rowland St, Whittier, CA 91748
213 N Citrus Ave, Covina, CA 91723

Publications

Us Patents

Modulation Of Metabolism Of Steroids And Xenobiotics

US Patent:
7413853, Aug 19, 2008
Filed:
Jul 9, 2002
Appl. No.:
10/482555
Inventors:
Ronald M. Evans - La Jolla CA,
Wen Xie - San Diego CA,
Assignee:
The Salk Institute for Biological Studies - La Jolla CA
International Classification:
C12Q 1/68
C12Q 1/48
C12Q 1/34
G01N 33/53
US Classification:
435 6, 435 78, 435 15, 435 18
Abstract:
In accordance with the present invention, there are provided methods for modulating Phase II conjugating enzymes such as, for example, UGTs. Phase II conjugating enzymes such as UGTs function in concert with Phase I monooxygenase enzymes such as cytochrome P450 enzymes (CYPs) to eliminate steroids and xenobiotics. Nuclear receptors SXR/PXR and CAR are xenosensors regulating expression of CYP genes such as CYP3A and 2B. The ability of this group of receptors to regulate expression of UGT in response to steroids and/or xenobiotics provides novel approaches for direct regulation/activation of a glucuronidation pathway, thereby providing methods to achieve physiologic homeostasis with respect to steroids and/or xenobiotics. SXR/PXR and CAR regulation/activation of UGT represents the first evidence of receptors that can transduce/transactivate both Phase I and Phase II adaptive hepatic response. In another aspect, the present invention also provides transgenic rodents expressing one or more of SXR, CAR or PXR.

Methods Of Treating Estrogen-Responsive Conditions By Orphan Nuclear Receptor Activation

US Patent:
2008008, Apr 10, 2008
Filed:
Aug 29, 2007
Appl. No.:
11/847163
Inventors:
Wen Xie - Pittsburgh PA,
Haibiao Gong - Pittsburgh PA,
Assignee:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 31/56
A61P 35/00
US Classification:
514182000
Abstract:
The invention provides a method of treating an estrogen responsive condition comprising administration of an agonist of an orphan nuclear receptor, wherein activation of the orphan nuclear receptor inhibits estrogen activity. The invention also provides a method of reducing the size of an estrogen responsive tumor comprising administration of an agonist of an orphan nuclear receptor, wherein activation of the orphan nuclear receptor inhibits estrogen activity. The invention also provides a pharmaceutical composition comprising an agonist of an orphan nuclear receptor and a pharmaceutically acceptable vehicle, wherein activation of the orphan nuclear receptor inhibits estrogen activity.

Constitutive Androstane Receptor (Car) As A Therapeutic Target For Obesity And Type Two Diabetes

US Patent:
2012000, Jan 5, 2012
Filed:
Nov 18, 2009
Appl. No.:
13/129711
Inventors:
Wen Xie - Pittsburgh PA,
Jie Gao - Pittsburgh PA,
Assignee:
UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA
International Classification:
A61K 36/282
A61K 31/515
A61K 31/37
A61P 3/10
A61K 31/429
A61K 31/7088
A61K 31/421
A61P 3/04
A61K 31/444
A61K 31/497
US Classification:
424740, 514335, 514270, 514457, 51425505, 514368, 514 44 R, 514374
Abstract:
The invention provides a method of controlling obesity or type two diabetes in a human. In accordance with the inventive method, the constitutive androstane receptor (CAR) is agonized within the human, which effectively controls obesity or type two diabetes.

Transgenic Mice Expressing A Human Sxr Receptor Polypeptide

US Patent:
6984773, Jan 10, 2006
Filed:
Dec 9, 1999
Appl. No.:
09/458366
Inventors:
Ronald M. Evans - La Jolla CA,
Bruce Blumberg - Irvine CA,
Wen Xie - San Diego CA,
Assignee:
The Salk Institute for Biological Studies - La Jolla CA
International Classification:
C12N 5/00
C12N 15/00
A01K 67/00
A01K 67/027
US Classification:
800 18, 800 8, 800 25, 435325
Abstract:
A novel nuclear receptor, termed the steroid and xenobiotic receptor (SXR), a broad-specificity sensing receptor that is a novel branch of the nuclear receptor superfamily, has been discovered. SXR forms a heterodimer with RXR that can bind to and induce transcription from response elements present in steroid-inducible cytochrome P450 genes in response to hundreds of natural and synthetic compounds with biological activity, including therapeutic steroids as well as dietary steroids and lipids. Instead of hundreds of receptors, one for each inducing compound, the invention SXR receptors monitor aggregate levels of inducers to trigger production of metabolizing enzymes in a coordinated metabolic pathway. Agonists and antagonists of SXR are administered to subjects to achieve a variety of therapeutic goals dependent upon modulating metabolism of one or more endogenous steroids or xenobiotics to establish homeostasis. An assay is provided for identifying steroid drugs that are likely to cause drug interaction if administered to a subject in therapeutic amounts.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.